9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
9-ING-41 is a small molecule potent selective GSK-3β inhibitor with antitumor activity. This
study investigates 9-ING-41 in combination with carboplatin chemotherapy in patients with
incurable, recurrent or metastatic salivary gland carcinomas (SGC). Patients with advanced
SGC (including all histologic subtypes and adenoid cystic carcinoma [ACC]) will receive
9-ING-41 intravenously (IV) along with carboplatin IV at standard dosing together on Day 1,
and 9-ING-41 alone on Day 4 of a 21-day cycle. Participants will be enrolled to two
histologic cohorts: Cohort 1 will be comprised of those with ACC, and Cohort 2 will include
patients with non-ACC SGC (or all other salivary gland cancer histologies). Treatment will
continue until progression of disease, death, or discontinuation of therapy for any reason.